临床肝胆病杂志2024，Vol.40Issue(8)：1682-1687,6.DOI:10.12449/JCH240828
直接抗病毒药物在丙型肝炎肝硬化患者中的应用进展
Advances in the application of direct-acting antivirals in patients with hepatitis C cirrhosis
摘要
Abstract
Chronic hepatitis C virus(HCV)infection can lead to liver cirrhosis,and complications after liver cirrhosis,including hepatocellular carcinoma(HCC),are the leading causes of death in patients with chronic liver diseases.Antiviral therapy can help to realize sustained virologic response,improve hepatitis and liver fibrosis,and delay disease progression.The safety and efficacy of direct-acting antivirals(DAAs)have been confirmed in patients with HCV-related liver cirrhosis,and whether DAAs can improve the complications and prognosis of patients with liver cirrhosis has gradually become a research hotspot.Related data are mainly reported by foreign scholars,and since DAAs have not been marketed in China for a long time,there is still a lack of mid-and long-term data.This article reviews the latest studies on the application of DAAs in patients with HCV-related liver cirrhosis and the impact of DAAs on clinical prognosis.关键词
肝炎病毒属/肝硬化/直接抗病毒药物/治疗结果Key words
Hepacivirus/Liver Cirrhosis/Direct-Acting Antivirals/Treatment Outcome引用本文复制引用
冉锡萍,蔡大川..直接抗病毒药物在丙型肝炎肝硬化患者中的应用进展[J].临床肝胆病杂志,2024,40(8):1682-1687,6.基金项目
重庆市科卫联合医学科研重点项目(2022ZDXM001) （2022ZDXM001）
重庆市首批公共卫生重点学科(专科) Chongqing Medical Scientific Research Key Project(Joint Project of Chongqing Health Commission and Science and Technology Bureau)(2022ZDXM001) （专科）
The First Batch of Key Disciplines on Public Health in Chongqing （）
